Publication: 49

Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).
      Google Scholar   
Citation:
J Clin Oncol vol 25 (21) 3124-9
Year:
2007
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Respiratory
Sec. Committees:
   
Pharmas:
 
Grants:
CA-25224, CA-35101, CA-35103, CA-35113, CA-35269, CA-35272, CA-35415, CA-35448, CA-37404, CA-37417, CA-52352, CA-60276, CA-63849  
Corr. Author:
 
Authors:
                         
Networks:
 
Study
NCCTG-95-20-53
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Small Cell, Cisplatin, Combined Modality Therapy, Dose Fractionation, Dose-Response Relationship, Drug, Dose-Response Relationship, Radiation, Etoposide, Female, Humans, Immunohistochemistry, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Prognosis, Radiotherapy, High-Energy, Risk Assessment, Survival Analysis, Treatment Outcome